Puma Biotechnology Inc (NASDAQ: PBYI) open the trading on Tuesday, with great promise as it jumped 7.47% to $3.02, before settling in for the price of $2.81 at the close. Taking a more long-term approach, PBYI posted a 52-week range of $2.22-$7.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -0.59%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -33.33%. This publicly-traded company’s shares outstanding now amounts to $49.07 million, simultaneously with a float of $34.86 million. The organization now has a market capitalization sitting at $159.32 million. At the time of writing, stock’s 50-day Moving Average stood at $2.94, while the 200-day Moving Average is $3.56.
Puma Biotechnology Inc (PBYI) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Puma Biotechnology Inc’s current insider ownership accounts for 28.99%, in contrast to 54.36% institutional ownership. According to the most recent insider trade that took place on Aug 12 ’24, this organization’s Director sold 23,358 shares at the rate of 3.49, making the entire transaction reach 81,466 in total value, affecting insider ownership by 47,000.
Puma Biotechnology Inc (PBYI) Earnings and Revenue Records
Puma Biotechnology Inc’s EPS decrease for this current 12-month fiscal period is -33.33% and is forecasted to reach 0.34 in the upcoming year.
Puma Biotechnology Inc (NASDAQ: PBYI) Trading Performance Indicators
Let’s observe the current performance indicators for Puma Biotechnology Inc (PBYI). It’s Quick Ratio in the last reported quarter now stands at 1.40. The Stock has managed to achieve an average true range (ATR) of 0.21. Alongside those numbers, its PE Ratio stands at $6.36, and its Beta score is 1.10. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.65. Similarly, its price to free cash flow for trailing twelve months is now 4.73.
In the same vein, PBYI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.47, a figure that is expected to reach 0.09 in the next quarter, and analysts are predicting that it will be 0.34 at the market close of one year from today.
Technical Analysis of Puma Biotechnology Inc (PBYI)
[Puma Biotechnology Inc, PBYI] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 31.94% While, its Average True Range was 0.21.
Raw Stochastic average of Puma Biotechnology Inc (PBYI) in the period of the previous 100 days is set at 41.73%, which indicates a major fall in contrast to 60.61% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 57.51% that was lower than 84.74% volatility it exhibited in the past 100-days period.
